Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE 2 OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASES

NCT00830180 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00830180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00830180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE 2 OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASES
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
October 29, 2009
Completion date
February 14, 2013
Enrollment
41 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, neoplasms